Rethinking Therapeutic Strategies for Anorexia Nervosa: Insights From Psychedelic Medicine and Animal Models

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Anorexia nervosa (AN) has a high mortality rate with limited effective treatments.
• Understanding AN's neurobiological drivers is critical for developing new therapies.
• Psychedelic research offers potential for treating mental disorders, including AN.

Purpose of the Study:

• To explore the potential of psychedelic medicine, specifically psilocybin, for treating anorexia nervosa.
• To investigate the neurobiological mechanisms underlying psychedelic effects in AN.
• To highlight the importance of animal models in psychedelic research for AN.

Main Methods:

• Review of current research on psychedelic medicine and AN.
• Discussion of findings from clinical trials in treatment-resistant depression.
• Emphasis on the utility of animal models, such as the activity-based anorexia (ABA) rodent model.

Main Results:

• Classical psychedelics may alleviate AN symptoms related to serotonergic signaling and cognitive inflexibility.
• Clinical trials with psychedelics show promise but have methodological limitations.
• Animal models offer a way to study neurobiological effects without human biases.

Conclusions:

• Further research into the neurobiological effects of psychedelics in animal models is essential.
• Animal studies can inform clinical applications and identify patient subpopulations who may benefit most from psychedelic therapy.
• Understanding psychedelic mechanisms is key to advancing AN treatment.